Acta Vet. Brno 2021, 90: 421-429
https://doi.org/10.2754/avb202190040421
The effect of etanercept and anakinra on experimental type 2 diabetes pathology in rats
References
1. A, Rahmat A, Othman F 2014: Effect of pomegranate on histopathology of liver and kidney on generated oxidative stress diabetic induced rats. J Cytol Histol 6: 2-5
2. AO, Idowu BA, Mafiana CF, Oluwalana SA, Ajayi OL, Akinloye OA 2012: Rat model of food-induced non-obese-type 2 diabetes mellitus: comparative pathophysiology and histopathology. Int J Physiol Pathophysiol Pharmacol 4: 51
3. MSH, Shen Q, Rehman K, Chen S 2012: Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 101: 1647-1658
<https://doi.org/10.1002/jps.23057>
4. MSH, Rehman K, Chen S 2013: Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 114: 525-531
<https://doi.org/10.1002/jcb.24402>
5. E, Lee Y, Phillips P, Perl A 2007: Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis 66: 1688
<https://doi.org/10.1136/ard.2007.072256>
6. A, Chawla R, Jaggi S 2016: Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab 20: 546
<https://doi.org/10.4103/2230-8210.183480>
7. Cheng D, Liang B, Li Y 2013: Antihyperglycemic effect of Ginkgo biloba extract in streptozotocin-induced diabetes in rats. BioMed Res Int: ID 162724, 7 p.
8. B, Bahcivan E, Eser Faki H, Uney K 2018: Combined treatment with interleukin-1 and tumor necrosis factor-alpha antagonists improve type 2 diabetes in rats. Can J Physiol Pharmacol 96: 751-756
<https://doi.org/10.1139/cjpp-2017-0769>
9. A, Gul H, Yesilyurt O, Ulas UH, Yildiz O 2011: Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 48: 135-142
<https://doi.org/10.1007/s00592-010-0237-x>
10. H, Storgaard H, Rask-Madsen C, Hermann TS, Ihlemann N, Nielsen DB, Spohr C, Kober L, Vaag A, Torp-Pedersen C 2005: Metabolic and vascular effects of tumor necrosis factor-α blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 42: 517-525
<https://doi.org/10.1159/000088261>
11. MY, Shoelson SE 2011: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11: 98-107
<https://doi.org/10.1038/nri2925>
12. JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G 2007: Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56: 2356-2370
<https://doi.org/10.2337/db06-1650>
13. JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, Irminger JC, Kergoat M, Portha B, Homo-Delarche F, Donath MY 2009: IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 106: 13998-14003
<https://doi.org/10.1073/pnas.0810087106>
14. C, Iroaganachi M, Eleazu K 2013: Ameliorative potentials of cocoyam (Colocasia esculenta L.) and unripe plantain (Musa paradisiacal L.) on renal and liver growth in streptozotocin induced diabetic rats. J Acute Dis 2: 140-147
<https://doi.org/10.1016/S2221-6189(13)60115-8>
15. E, Nejati V, Khazaei M 2016: Antioxidant and protective effects of Royal jelly on histopathological changes in testis of diabetic rats. Int J Reprod Med 14: 519-526
16. S, Geetha A 2017: Study on the impact of family history of diabetes among type 2 diabetes mellitus patients in an urban area of Kancheepuram district, Tamil Nadu. Int J Community Med Public Heal 4: 4151-4156
17. S-i, Kajimoto Y, Umayahara Y, Kaneto H, Watada H, Kuroda A, Kawamori D, Yasuda T, Matsuhisa M, Yamasaki Y 2002: Probucol preserves pancreatic β-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract 57: 1-10
<https://doi.org/10.1016/S0168-8227(02)00005-0>
18. VA, Jacobo P, Theas MS, Lustig L 2009: Cytokines and chemokines in testicular inflammation: a brief review. Microsc Res Tech 72: 620-628
<https://doi.org/10.1002/jemt.20704>
19. E, Tugyan K, Ozturk H, Gumustekin M, Cilaker S, Uysal N 2008: Effect of melatonin on testicular damage in streptozotocin-induced diabetes rats. Eur Surg Res 40: 354-360
<https://doi.org/10.1159/000118032>
20. KA, Reynolds CM, McGillicuddy FC, Roche HM 2011: Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc 70: 408-417
<https://doi.org/10.1017/S0029665111000565>
21. MD 2015: Silibinin, a bioactive flavanone, prevents the progression of early diabetic nephropathy in experimental type‐2 diabetic rats. Int J Green Pharm 9: 118-124
<https://doi.org/10.4103/0973-8258.155060>
22. KN, Calton EK, Carlessi R, Hart PH, Newsholme P 2017: The bioenergetics of inflammation: insights into obesity and type 2 diabetes. Eur J Clin Nutr 71: 904-912
<https://doi.org/10.1038/ejcn.2017.45>
23. B, Lee Y, Kim E, Kwak A, Ryoo S, Bae S, Azam T, Kim S, Dinarello CA 2013: The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol 4: 391
24. CM, Faulenbach M, Vaag A, Vřlund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY 2007: Interleukin-1–receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526
<https://doi.org/10.1056/NEJMoa065213>
25. L, Qiu H, Cai B, Chen N, Lu X, Zheng S, Ye X, Li Y 2018: Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway. Oncotarget 9: 5321-5336
<https://doi.org/10.18632/oncotarget.23915>
26. Luna L 1968: Routine staining procedures. Manual of histologic staining methods of the Armed Forces Institute of Pathology. Blakiston Division McGraw-Hill, New York, 258 p.
27. K, Dharmadhikari G, Schumann DM, Střrling J 2009: Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 9: 1177-1188
<https://doi.org/10.1517/14712590903136688>
28. M, Pawlick R, Kin T, Shapiro A 2012: Anakinra potentiates the protective effects of etanercept in transplantation of marginal mass human islets in immunodeficient mice. Am J Transplant 12: 322-329
<https://doi.org/10.1111/j.1600-6143.2011.03796.x>
29. P, Bahadoran Z, Azizi F 2014: Functional foods-based diet as a novel dietary approach for management of type 2 diabetes and its complications: A review. World J Diabetes 5: 267-281
<https://doi.org/10.4239/wjd.v5.i3.267>
30. H, Ahrén B, Sundler F 1996: Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats. Diabetologia 39: 649-657
<https://doi.org/10.1007/BF00418536>
31. O, Akalin PP, Baspinar N, Hatipoglu F 2009: Pathological changes in the acute phase of streptozotocin-induced diabetic rats. Bull Vet Inst Pulawy 53: 783-790
32. AO, Baboolal K, Riley S, Gröne H, Janssen U, Steadman R, Williams J, Floege J 2001: Association of prolonged hyperglycemia with glomerular hypertrophy and renal basement membrane thickening in the Goto Kakizaki model of non–insulin-dependent diabetes mellitus. Am J Kidney Dis 37: 400-410
<https://doi.org/10.1053/ajkd.2001.21322>
33. K, Akash MSH 2016: Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci 23: 1-18
<https://doi.org/10.1186/s12929-016-0303-y>
34. K, Onderci M, Tuzcu M, Ustundag B, Cikim G, Ozercan İH, Sriramoju V, Juturu V, Komorowski JR 2007: Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat. Metabolism 56: 1233-1240
<https://doi.org/10.1016/j.metabol.2007.04.021>
35. K Viswanad B, Asrat L, Kaul CL, Ramarao P 2005: Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2: 313-320
<https://doi.org/10.1016/j.phrs.2005.05.004>
36. TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, Khor VK, Ahima RS, Grinspoon SK 2011: TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 96: 146-150
<https://doi.org/10.1210/jc.2010-1170>
37. M, Yamato H, Hayashi T, Ochiai H, Kakuchi J, Goto S, Nishijima F, Lino N, Kazama JJ, Takeuchi T 2006: High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy. Nutr Metab Cardiovasc Dis 16: 477-484
<https://doi.org/10.1016/j.numecd.2005.08.007>
38. JJ, Rajarajeswari D, Naidu J 2012: Association of TNF-α with insulin resistance in type 2 diabetes mellitus. Indian J Med Res 135: 127-130
<https://doi.org/10.4103/0971-5916.93435>
39. P, Wood I 2005: Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 33: 1078-81.
<https://doi.org/10.1042/BST0331078>
40. N, Iraz M, Öztürk F, Uçar M, Gül M, Eşrefoğlu M, Otlu A 2005: Improving effects of melatonin on the histologic alterations of rat kidneys induced by experimental diabetes. J Inonu Univ Med Fac 12: 145-152
41. KE, Hotamisligil GS 2005: Inflammation, stress, and diabetes. J Clin Investig 115: 1111-1119
<https://doi.org/10.1172/JCI25102>
42. IC 2000: Radicals and oxidative stress in diabetes. Diabet Med 17: 171-180
<https://doi.org/10.1046/j.1464-5491.2000.00259.x>
43. R, Le G, Li A, Zheng J, Shi Y 2006: Effect of antioxidant capacity on blood lipid metabolism and lipoprotein lipase activity of rats fed a high-fat diet. Nutrition 22: 1185-1191
<https://doi.org/10.1016/j.nut.2006.08.018>
44. M, Naqvi SN-u-H 2010: Effects of STZ-induced diabetes on the relative weights of kidney, liver and pancreas in albino rats: a comparative study. Int J Morphol 28: 135-142
<https://doi.org/10.4067/S0717-95022010000100019>
